Sanofi-Aventis Acomplia Phase III obesity data

Sanofi-Aventis (Euronext: SAN; SNY) said one-year data from the U.S. and European double-blind two-year Phase III RIO-Europe trial showed Acomplia rimonabant significantly reduced body weight compared...